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Wortmannin (Wm), a steroid-like molecule of
428.4 Da, appears to be unstable in biological
fluids (apparent chemical instability), yet it ex-
hibits an antiproliferative activity in assays em-
ploying a 48 hr incubation period (prolonged
bioactivity), a situation we refer to as the ‘‘wort-
mannin paradox.’’ Under physiological condi-
tions, Wm covalently reacts with nucleophiles
such as the side chains of cysteine, N-methyl
hexanoic acid, lysine, or proline at the C20 posi-
tion on the furan ring. Like Wm, WmC20 amino
acid derivatives had significant antiproliferative
activities. Three Wm derivatives, WmC20-pro-
line, WmC20-cysteine, and a WmC20-N-methyl
hexanoic acid, generatedWm that then reacted
with lysine in an exchange-type reaction. This
unusual, reversible, covalent reaction of Wm
with nucleophiles under physiological condi-
tions provides an explanation for the wortman-
nin paradox.
INTRODUCTION
The central role played by PI3 kinases in a variety of
metabolic processes suggests that the inhibition of this
activity may be therapeutic in diverse diseases including
cancer [1], inflammatory conditions [2], or coagulation dis-
orders [3].Wortmannin (Wm), a PI3 kinase inhibitor, is a fre-
quent tool in chemical genomics and is used to help define
the PI3 kinase dependence of biological processes such
as histamine release and insulin action [4–6]. Wm inhibits
PI3 kinases in a nonisotype-specific manner by covalently
reacting with a lysine in the catalytic subunit of the enzyme
[7, 8]. Current efforts to develop PI3 kinase inhibitors as
drugs include both Wm-based pharmaceuticals [9, 10]
and man-made, isotype-specific inhibitors [11, 12].
However, the comparison between isotype-selective
PI3 kinase inhibitors and Wm-based pharmaceuticals as
well as the use of Wm as a tool in chemical genomics
are both complicated by the fact that Wm is a chemically
reactive molecule and has been described as unstableChemistry & Biology 14, 3(see [13–15]). We recently observed that Wm’s stability
was highly dependent on the presence of nucleophiles;
in nucleophile-free, aqueous systems, Wm was stable
(half-life = 57.8 hr in PBS), and the addition of nucleophiles
like amino acids hastened its disappearance (half-life = 22
min in PBS plus 10 mM proline) [16]. If, however, Wm re-
acts with common nucleophiles, its ability to pass through
nucleophile-rich intracellular or extracellular fluids, and to
modify a molecular target like PI3 kinase, would seem to
be unexplained. Also unclear is how the reactive Wmmol-
ecule might exert antiproliferative effects when it is added
to nucleophile-rich culture media and cells are allowed to
proliferate, typically for 48 hr. An improved understanding
of the interrelated issues of stability and chemical reactiv-
ity would seem to be required if Wm is to be used to define
the PI3 kinase dependence of biological processes or if
Wm-based compounds are to be used as sources of
potential pharmaceuticals.
Here, we present an explanation for what we term ‘‘the
wortmannin paradox,’’ or the ability of a chemically unsta-
ble molecule to exert biological effects that seem to re-
quire its persistence for hours to days.We show that under
physiological conditions, the conjugated 2,4-diacylfuran
system of Wm covalently and reversibly reacts at the
C20 position with the side chains of certain amino acids,
yielding WmC20 derivatives, which, like Wm, exhibit an
antiproliferative activity. The 2,4-diacetylfuran system of
the Wm molecule is a unique, to our knowledge, conju-
gated system that can both form and break covalent
bonds at significant rates under physiological conditions.
RESULTS
Our investigation into the reaction of Wmwith amino acids
was initiated by the use of Wm in assays that measure the
ability of a compound to antagonize cell proliferation over
a 48–72 hr incubation period [17–19], when Wm’s half-life
in a variety of tissue culture media was reported to be
about 10 min [13]. We first confirmed the instability of
Wm in RPMI culture media by HPLC, as shown in
Figure 1A, in which chromatograms of Wm in media for
less than 1, 2, and 5 min are shown. The area of the Wm
peak was fit to a first-order decay process (Figure 1B) to
yield a rate constant of 0.70 min1, which corresponds
to a half-life of 0.99 min. We therefore concluded that21–328, March 2007 ª2007 Elsevier Ltd All rights reserved 321
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Wortmannin Paradox: ‘Instability’ with BioactivityFigure 1. Fate of Wortmannin and Its
Antiproliferative Activity in Tissue Cul-
ture Media
(A) Wortmannin (Wm) was incubated in culture
media for the indicated times and subjected to
HPLC. The rapid disappearance of Wm was
associated with the appearance of a large
number of peaks.
(B) First-order decay plot for the disappear-
ance of Wm. The first-order decay constant
was 0.70 min1, which corresponded to a
half-life of 0.99 min.
(C) Wm was aged in tissue culture media for
varying times and was added at 50 mM to cells
that were then allowed to proliferate for an ad-
ditional 48 hr. Survival was reduced to 40%–
45% of cells not treated with Wm, regardless
of Wm’s incubation in culture media. Error
bars indicate standard deviation.
(D) Inhibition of cell proliferation as a function of
Wm concentration when Wm was added di-
rectly to media plus cells. The arrow indicates
inhibition achieved by the 50 mM Wm concen-
tration used in (C). The IC50 is given in Table
1. Wm rapidly disappears in culture media
but exerts an antiproliferative activity after its
disappearance. Error bars indicate standard
deviation of four replicates.Wm was at least as unstable in culture as reported [13].
We next examined the antiproliferative activity of Wm in
tissue culture media by incubating Wm in the same
RPMI media as that used in Figure 1A for varying time pe-
riods, up to 240 min. We then added the media with aged
Wm to A549 cells whose proliferation was examined over
an additional period of 48 hr, as shown in Figure 1C.
Though the half-life of Wm was 0.99 min in media, Wm in-
cubated inmedia for up to 4 hr inhibited cell proliferation in
a manner similar to the same concentration of Wm (50 mM)
added to media plus cells (p > 0.5 in all cases). The inhibi-
tion of cell proliferation as a function of Wm concentration
is shown in Figure 1D (IC50 = 11.5 mM; also see Table 1).
We therefore hypothesized that whenWmwas added to
culture media, it was converted into a form or forms that322 Chemistry & Biology 14, 321–328, March 2007 ª2007 Elsevhad an antiproliferative activity. We had previously ob-
served that Wm was stable in PBS, but that its disappear-
ance was hastened by the addition of amino acids or pro-
tein (Table 1 of [16]), which suggested that Wm might be
reacting with amino acids. We therefore hypothesized
that the addition ofWm to culturemedia resulted in the for-
mation of WmC20 amino acid derivatives that maintained
an antiproliferative activity due to their ability to regenerate
Wm through non-enzyme-catalyzed, reversible, covalent
reactions at the C20 position, as shown in Figure 2. The
model is supported by observations outlined below: (1)
Wm reacts with amino acids under physiological condi-
tions to form WmC20 derivatives; (2) WmC20 derivatives
exhibit an antiproliferative activity and are inhibitors of
PI3 kinase; (3) WmC20 derivatives generate Wm; (4)Table 1. Reaction of Wortmannin with Amino Acid Derivatives or Proline in PBS or DMSO Plus TEA
Wm and Amino
Acids in PBS Wm Wm and Proline
Wm and
N-Acetyl-Lysine
Wm and
N-Acetyl-Cysteine Wm and NMeHA
Retention time (Figure 3) 40.80a, 13.23b 34.09a 37.20a 35.33a 11.31b
Wm and amino
acids in DMSO (Figure 4)
1 2 3 4
Yield 99.5% 78.4% 81.8% 68.9%
Retention time 34.12 37.10 35.20 11.34b
Molecular weight obtained 544.2179 (M+H+) 617.2739 (M+H+) 592.1856 (M+H+) 574.2652 (M+H+)
Molecular weight predicted 544.2182 617.2710 592.1852 574.2648
IC50, (mM) Antiproliferation 11.5 ± 0.5 1.79 ± 0.18 29.8 ± 0.9 8.6 ± 0.3 2.10 ± 0.20
aa, amino acid; TEA, triethylamine; DMSO, dimethylsulfoxide.
a HPLC system 4.
bHPLC system 5.ier Ltd All rights reserved
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Wortmannin Paradox: ‘Instability’ with BioactivityFigure 2. Proposed Mechanism of Wort-
mannin Disappearance in Culture Media
The structure and number systems of wort-
mannin (Wm) are given with the 2,4-diacetyl-
furan ring denoted. The model proposes that
Wm reacts with biological nucleophiles at the
C20 position. Due to an intramolecular attack
by the hydroxyl group at C6, WmC20 deri-
vatives can form Wm, but the position of the
equilibrium is to the right. Wm numbering is
shown.when a WmC20 derivative generates Wm in the presence
of a large excess of a second reactive amino acid, the
newly formed Wm should react with the second amino
acid; and (5) the WmC20 derivatives that generate Wm
inhibit PI3 kinase.
To understand the reaction of Wm with amino acids un-
der physiological conditions, we incubated 1.35 mM Wm
with amino acid derivatives or proline (1.35 mM, PBS,
pH 6.8, 37C) for 22 hr and subjected the resulting mix-
tures to HPLC. No evidence of reaction was seen with
N-acetyl-tryptophan, N-acetyl-tyrosine, N-benzoyl-argi-
nine, or N-benzoyl-histidine. However, when Wm was
incubated with proline (Figure 3A), N-acetyl-lysine (Fig-
ure 3B), N-acetyl-cysteine (Figure 3C), or N-methyl hexa-
noic acid (NMeHA) (Figure 3D), new peaks were readily
apparent. To investigate the Wm derivatives obtained in
PBS, we then prepared four WmC20 amino acid deriva-
tives in DMSO and TEA, as shown in Figure 4: 1, or
WmC20-pro; 2, or WmC20-lys; 3, or WmC20-cys; and 4,
or WmC20-NMeHA. Each of the four new peaks formed
when Wm was incubated with proline, NMeHA, or amino
acid derivatives (Figures 3A–3D) had retention times cor-
responding to those of the expected WmC20 derivative
prepared in DMSO and are therefore identified as suchChemistry & Biology 14, 321in the figure. The retention times of the new peaks ob-
tained in PBS are compared with the retention times of
WmC20 derivatives prepared in DMSO in Table 1. Table
1 also gives the mass of the Wm derivatives prepared in
DMSO compared to those predicted for these com-
pounds. Reaction at the C20 position of the Wmmolecule
was indicated by an analysis of NMR peaks. We conclude
that Wm reacts with the epsilon amino group of lysine, the
sulfhydryl group of cysteine, and the secondary amine of
proline under physiological conditions to yield WmC20
derivatives.
To examine the second prediction of the model shown
in Figure 2, we determined the IC50s of Wm, 1, 2, 3, and
4 by using A549 cells in an antiproliferative assay in which
these compoundswere added tomedia plus cells once, at
the start of the 48 hr assay period. IC50s are given in Table
1. The IC50s of compounds 1, 2, 3, and 4were moderately
higher or lower than Wm, but all had significant antiproli-
ferative effects.
The hypothesis that WmC20 derivatives might undergo
exchange reactions is shown in Figure 5A, in which the ex-
change reactions between 1, 3, and 4, and N-acetyl-lysine
are shown. As shown in Figure 5B, when WmC20-pro or 1
(0.3 mM) was incubated with N-acetyl-lysine (3 mM), WmFigure 3. Nonenzymatic Reaction of
Wortmannin with Amino Acid Side
Chains under Physiological Conditions
(A–D) (A) Wortmannin (Wm) (1.5 mM) was incu-
bated with 1.5 mM proline (PBS, pH 6.8, 37C)
for 3 and 22 hr and was analyzed by HPLC. The
compound formed cochromatographed with
compound 1 made in DMSO. (B–D) Wm was
incubated with (B) N-acetyl-lysine, (C) N-ace-
tyl-cysteine, or (D) NMeHA. Again, Wm deriva-
tives formed in PBS cochromatographed with
compounds made in DMSO. Retention times
are given in Table 1. HPLC system 4 was used
for (A)–(C), while system 5 was used for (D).–328, March 2007 ª2007 Elsevier Ltd All rights reserved 323
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Amino Acid Derivatives
Wortmannin C20 amino acid derivatives were
prepared in DMSO and TEA.formed in transient fashion during incubations of 1–5 hr.
However, by 20 hr, both Wm and 1 had disappeared,
and a peak corresponding to pure WmC20-lys, 2, made
in an organic solvent was the only peak obtained. When
the same experiment was performed with WmC20-cys,
3, the transient formation of Wm was again seen, with
the final formation of 2 (Figure 5C). Identical results were
obtained when 4, WmC20-NMeHA, was incubated with
N-acetyl-lysine (data not shown). However, when 2was in-
cubated with proline or N-acetyl-cysteine, no evidence of
a reactionwas seen (Figures 5D and 5E).We conclude that
the incubation of 1, 3, or 4 with N-acetyl-lysine produced
Wm as a stable intermediate, which then reacted with
the epsilon amino group N-acetyl-lysine to yield 2. The
net effect is a replacement of N-acetyl-cysteine, proline,
or NMeHA with N-acetyl-lysine at the C20 position of Wm.
Finally, we assessed the ability of the fourWmC20 deriv-
atives to inhibit PI3 kinase,whichemploys a30min incuba-
tion, as shown in Table 2. Each derivative was also evalu-
ated for its ability to produceWm.WmC20 derivatives that
inhibited PI3 kinase producedWm under conditions of the
enzyme assay, a correlation discussed further below.
DISCUSSION
We propose that an equilibrium exists between Wm and
WmC20-modified derivatives under physiological condi-
tions (pH 6.8, 37C, presence of nucleophiles), as shown
in Figure 2. Evidence supporting this view is derived
from four observations: (1) Wm reacts at the C20 position
with amino acids under physiological conditions; (2)
WmC20 amino acid derivatives are active in antiprolifera-
tive assays; (3) WmC20 amino acids produce Wm, which
then reacts with other amino acids in exchange reactions;
and (4) the strength of WmC20 derivatives as inhibitors of
PI3 kinase, IC50, parallels their ability to generate Wm.
Reaction of Wm at C20 with Amino Acid Side Chains
The C20 position of Wm reacts with amino acid side
chains of lysine and cysteine or proline (PBS, pH 6.8,
37C), not with the side chains of tryptophan, histidine, ty-324 Chemistry & Biology 14, 321–328, March 2007 ª2007 Elserosine, or arginine. The nucleophilicites of the nitrogens or
oxygens of histidine, tryptophan, tyrosine, and arginine
are reduced because of the partial electron delocalization
via a p-p conjugation when they are deprotonated. On the
other hand, the nitrogens of lysine, proline, and NMeHA
and the sulfur of cysteine feature more localized electrons
and are more strongly nucleophilic. When incubated with
Wm, these nucleophiles react with the C20 of Wm, which
is electrophilic due to (1) the electron-withdrawing nature
of the two carbonyl groups of the 2,4-diacylfuran ring
and (2) the strain on the furan ring system conferred by
the rest of the Wm molecule. Earlier studies on WmC20
derivatives used organic solvents and base for their
preparation [20–22]. Here, we show that the reactions
between Wm and amino acids at the C20 position occur
under physiological conditions, and that the products
made are the same as those made under organic
conditions.
Antiproliferative Activity of WmC20 Derivatives
The WmC20 derivatives that we prepared exhibited IC50s
in an antiproliferative assay that were modestly lower (1,
or WmC20-pro; 3, or WmC20-cys; and 4, or WmC20-
NMeHA) or higher (2, or WmC20-lys) than Wm. The anti-
proliferative activity of WmC20 derivatives has been
reported [9, 21, 22].
Exchange Reaction of WmC20 Derivatives Due to
Wm Formation
The ability of Wm to react with amino acids under phys-
iological conditions (forward reactions in Figure 2 and
Figure 5A), together with our earlier observation that
WmC20 derivatives can produce Wm [16] (reverse reac-
tion in Figure 2), suggested that an exchange reaction in-
volving WmC20 amino acid derivatives and amino acids
might be possible. When incubated with N-acetyl-lysine,
WmC20 derivatives 1 and 3 produced Wm and eventually
formed 2 (Figures 5B and 5C). (Compound 4 was also in-
cubated with N-acetyl-lysine with similar results [data not
shown].) The accumulation of 2 or WmC20-lys with ex-
change reactions requires that this Wm derivative, onevier Ltd All rights reserved
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other derivatives. The increased stability of 2 relative to
3, 4, or 1 results from the presence of a hydrogen-bond
stabilization of 2, as shown in Figure 5, a structure first
proposed by Norman et al. [20] and confirmed by Yuan
et al. [16]. The stability of 2 was also apparent from the in-
ability of its N-acetyl-lysine to exchange with proline or N-
acetyl-cysteine (Figures 5D and 5E). It should be noted
that for the exchange reaction to occur, Wm must be sta-
ble in the aqueous media employed, consistent with our
observation of its stability [16].
Figure 5. Exchange Reactions Involving Wortmannin C20
Amino Acid Derivatives
(A) Wortmannin C20 derivatives lacking hydrogen-bond stabilization,
1, 3, and 4, generate Wm, which reacts with the N-acetyl-lysine pres-
ent to form 2. Since 2 is the low-free energy compound due to hydro-
gen-bond stabilization, a reaction of N-acetyl-cysteine or proline with 2
does not yield 1 or 3. The exchange reactions proposed in (A) were
monitored by HPLC in (B)–(E).
(B) Incubation of 1 with N-acetyl-lysine (PBS, pH 6.8, 37C). With time,
1 disappears with the formation of Wm (1–5 hr), which then disappears
with the formation of 2 by 20 hr.
(C) Incubation of 3 with N-acetyl-lysine. With time, 3 disappears with
the formation of Wm (1–5 hr); 2 eventually forms at 20 hr.
(D and E) No exchange occurs between 2 and (D) proline or (E) N-ace-
tyl-cysteine.Chemistry & Biology 14, 32Inhibition of PI3 Kinase
To determine whether the inhibition of PI3 kinase by
WmC20 derivatives was consistent with the model shown
in Figure 2, in which Wm is the predominant active com-
pound, we measured the ability of WmC20 derivatives to
inhibit PI3 kinase and compared that with the generation
of Wm by HPLC. As shown in Table 2, pure WmC20-lys
did not inhibit PI3 kinase and did not generate detectable
Wm in the time of the assay (30 min). Three other WmC20
derivatives (WmC20-pro, WmC20-cys, and WmC20-
NMeHA) inhibited PI3 kinase with higher IC50s than Wm;
the higher IC50 results from the partial conversion to Wm
during the 30 min incubation time of the PI3 kinase assay.
For the four WmC20 derivatives evaluated, the amount of
Wm generated was roughly proportional to the potency of
WmC20 derivatives as PI3 kinase inhibitors. The IC50s for
the inhibition of PI3 kinase were far lower than their IC50s
for the inhibition of cell proliferation (Table 2), as noted by
others [9, 19].
The model of reversible Wm formation (Figure 2) pro-
vides a general fate of Wm in nucleophile-rich biological
systems, proposing that the bulk of the Wm exists as
WmC20 derivatives that have a bioactivity due to the re-
versible formation of Wm. Evidence for the formation of
WmC20 derivatives under physiological conditions (for-
ward reaction shown in Figure 2) is provided by the disap-
pearance of Wm in culture media (Figure 1A) and the reac-
tion ofWmwith amino acid side chains (Figure 3). Evidence
for simultaneous forward and reverse reactions (an equi-
librium) is provided by the exchange reactions demon-
strated in Figures 5B and 5C. Evidence for the formation
of Wm from pure WmC20 derivatives is provided by the
ability ofWmC20derivatives to inhibit PI3 kinase in propor-
tion to the amount of Wm generated (Table 2). Thus, the
model provides an explanation for the observation that
some WmC20 derivatives inhibit PI3 kinase (see Table 2
and [20]), in spite of the fact that the C20 of the furan ring
reacts with a lysine in the ATP site of PI3 kinase [23];
WmC20 derivatives that inhibit PI3 kinase are those that
generate Wm over the 30 min assay period (reverse reac-
tion of Figure 2). A feature of the model is the slow, tran-
sient generation of Wm that occurs (Figures 5B and 5C),
Table 2. Inhibition of PI3 Kinase and Wortmannin
Generation by WmC20 Derivatives
Compound
IC50 PI3 K
(nM)
Relative
IC50
a
Wm Generationb
(30 min, 25C, PBS)
Wm 12 1.00 1.00
WmC20-lys, 2 >1000 0 <0.001
WmC20-pro, 1 68 0.18 0.051
WmC20-cys, 3 1144 0.010 0.006
WmC20-NMeHA, 4 108 0.11 0.036
a IC50 for Wm divided by IC50 of compound.
bWm generation (30 min, 25C) was measured by HPLC. Wm
is expressed as fraction of the initial Wm present. Incubation
for PI3 kinase assay was also performed at 30 min at 25C.1–328, March 2007 ª2007 Elsevier Ltd All rights reserved 325
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can be antiproliferative during a 48 hr assay (Table 1).
The model shown in Figure 2 requires a specific rela-
tionship between two potential sources of Wm instability
in biological systems—a slow hydrolytic opening of the
lactone ring and fast reaction of nucleophiles at C20.
The stability of Wm required to obtain the simple chro-
matograms shown in Figure 5 is consistent with a long
half-life for Wm in PBS (without nucleophiles) and demon-
strates the slow opening of the lactone ring. The stability of
Wm in PBS was previously determined to be 57.8 hr [16].
The major source of ‘‘instability’’ of Wm is the reaction of
nucleophiles at C20, which causes Wm to rapidly disap-
pear in culture media (half-life of 0.99 min in culture media,
Figure 1A), or 22 min in PBS plus proline [16]. Consistent
with the view that Wm instability is due to a reaction at
the C20 of the 2,4-diaceylfuran ring system with nucleo-
philes, and not to lactone hydrolysis, is the stability of lac-
tone-containing natural products. The stability of com-
pounds like digoxin, warfarin, etoposide, and irinotecan
is sufficient for their use as pharmaceuticals.
Wm-related compounds have long been investigated as
antiinflammatory [24] and anticancer agents [9, 18, 19, 21],
and they have been rejected for pharmaceutical develop-
ment due to toxicity and stability considerations [14, 15].
The complex behavior of Wm in biological systems sug-
gests that an understanding of the fate of Wm-derived
compounds may have to accompany all investigations
into their efficacy and toxicity. For example, the relative
activity of panels of Wm derivatives may reflect the con-
version of Wm-based compounds to active and inactive
molecules, rather than structure activity relationships
predicated on the binding of compounds in the form syn-
thesized to a molecular target(s). However, determining
the fate of Wm in biological systems is complicated by
the large number of molecules with which it can react (pri-
mary amines, secondary amines, thiols), yielding products
with widely varying properties. Not only can the nonpolar
Wm molecule form low-molecular weight, charged, or
uncharged compounds by reaction with low-molecular
weight nucleophiles, but it can likely react with high-mo-
lecular weight nucleophiles as well. On gels, a number of
wortmannylated proteins were observed, when a fluores-
cent Wm was reacted with cells or cell lysates [25], and
may reflect the formation of WmC20-modified proteins.
Multiple methodologies will likely be needed for following
Wm, a steroid-like molecule of 428.4 Da that can react
with a variety of nucleophilic species. The model shown
in Figure 2, proposing the interconversion between Wm
and WmC20 derivatives, provides a useful hypothesis
for further investigations into the complex behavior of
Wm in biological systems.
SIGNIFICANCE
Amodel for the fate ofWm in biological fluids, in which
the active species,Wm, exists in equilibriumwith inac-
tive WmC20 derivatives, and which accounts for Wm’s
apparent instability and prolonged bioactivity, is pro-326 Chemistry & Biology 14, 321–328, March 2007 ª2007 Elsevposed. Wm covalently reacts with a lysine in the ATP
site of PI3 kinase to inhibit the enzyme; however,
Wm’s target specificity is limited, and non-target-re-
lated covalent reactions, such as the reaction with
certain amino acids, occur. Other natural products
that modify biological targets and react more gener-
ally include the penicillins, which modify peptidases
involved with bacterial cell wall synthesis [26] and
also react with the epsilon amino groups of lysines
[27]. Similarly, aspirin acetylates its target cyclooxy-
genase and a variety of other proteins [26]. Thus, sim-
ilar to what is seen with other reactive natural prod-
ucts, Wm reacts both with a biological target and
other nucleophiles. However, the reactions of Wm
are unusual for the following reasons. First, Wm’s re-
action with amino acids results in only moderate de-
creases of its antiproliferative activity, as is the case
with lysine, or results in increased antiproliferative
activity, as is the case with proline, cysteine, and
NMeHA. Second, Wm’s reaction with amino acids is
reversible, generating Wm. Understanding the un-
usual and complex fates of chemically reactive natural
products like Wm in biological systems is essential if
we are to properly use such materials as selective in-
hibitors of biological processes or design pharmaceu-
ticals based on them.
EXPERIMENTAL PROCEDURES
General
Wortmannin (Wm) was a gift of the natural products branch of the Na-
tional Cancer Institute. All reagents and solvents were of standard
quality. NMR was performed on a Varian 400 MHz instrument with
CDCl3. Mass spectra were obtained on a Micromass LCT instrument
by using the time-of-flight ESI technique. HPLC (Varian Prostar 210
with a variable wavelength PDA 330 detector) employed reverse-
phase C18 columns (VYDAC, Cat. #: 218TP1022 for synthesis; Varian,
Cat. #: R0086200C5 for analysis) with water (Millipore, containing
0.1% trifluoroacetic acid) (buffer A) and acetonitrile (containing 20%
buffer A) (buffer B) as the elution buffers. System 1 (used for purification
of 1): buffer A:buffer B (80:20) isocratic for 5 min, linear gradient to
buffer A:buffer B (20:80) over 20 min, then gradient back to 80:20
(buffer A:buffer B) for 5 min and isocratic for 5 min, flow: 4.9 ml/min,
lmax: 410 nm). System 2 (used for purification of 2): buffer A:buffer B
(80:20) isocratic for 5 min, linear gradient to buffer A:buffer B (0:100)
over 30 min, then gradient back to 80:20 (buffer A:buffer B) for 5 min
and isocratic for 5 min, flow: 6.0 ml/min, lmax: 255 nm. System 3
(used for purification of 3): buffer A:buffer B (80:20) isocratic for 5
min, linear gradient to buffer A:buffer B (20:80) over 45 min, then gra-
dient back to 80:20 (buffer A:buffer B) for 5 min and isocratic for 5
min, flow: 4.9 ml/min, lmax: 410 nm. System 4: buffer A:buffer B
(99:1) linear gradient to buffer A:buffer B (40:60) over 46 min, then gra-
dient back to 90:1 (buffer A:buffer B) for 5 min and isocratic for 5 min,
flow: 1.0 ml/min, lmax: 254 nm. System 5: buffer A:buffer B (70:30) lin-
ear gradient to buffer A:buffer B (20:80) over 15min, then gradient back
to 70:30 (buffer A:buffer B) for 3 min and isocratic for 5 min, flow: 1.0
ml/min. lmax: 258 nm.
Syntheses of Wm C20 Derivatives 1, 2, and 3
To synthesize 1, Wm (10.7 mg, 0.025 mmol) and proline (5.75 mg, 0.05
mmol) were mixed in anhydrous DMSO (0.5 ml). The mixture was
stirred at room temperature for 1 hr. After dilution with 50% acetonitrile
in water (1:1), the mixture was purified by HPLC (system 1) and gave
a yellow powder after lyophilization. Analysis of 1 by HPLC (systemier Ltd All rights reserved
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544.2182, found 544.2179 (M+H+); 1H NMR, (CDCl3): 0.86 (3H, s, 13-
CH3), 1.31–1.35 (1H, t, J = 8 Hz), 1.57 (3H, s, 10-CH3), 1.70–2.00
(5H, b), 2.15 (3H, s, CH3COO), 2.20–2.35 (2H, m), 2.35–2.45 (1H, m),
2.55–2.64 (2H, m), 2.90–3.00 (2H, m), 3.10–3.20 (3H, m), 3.25 (3H, s),
3.40–3.50 (1H, b), 4.50–4.65 (2H, m), 6.00–6.10 (1H, b, H-11), 8.28
(1H, s, H-20).
To synthesize 2, Wm (12.8mg, 0.03mmol), N-acetyl-lysine (28.2mg,
0.15 mmol), and triethylamine (30 ml) were mixed in a mixture of DMSO
(1 ml), methanol (1 ml), and water (100 ml). After 1 hr of stirring, the re-
action mixture was purified by HPLC (system 2), and a yellow powder
was obtained after lyophilization. The purity of compound 2 was con-
firmed by HPLC as 100% (system 4). Yield: 14.5 mg, 78.4%. MS:
C31H40N2O11, cal. 617.2710, found 617.2739 (M+H
+); NMR (CDCl3,
ppm): 0.81 (3H, s, 13-CH3), 1.38–1.60 (2H, m), 1.52 (3H, s, 10-CH3),
1.64–1.76 (2H, m), 1.82–1.96 (3H, m), 2.04 (3H, s, NHCOCH3), 2.06
(3H, s, CH3COO), 2.22–2.40 (3H, m), 2.50–2.63 (1H, m), 2.80–2.99
(2H, m,), 3.16–3.24 (2H, m), 3.26 (3H, s, CH3OCH2), 3.36–3.52 (2H,
m), 3.52–3.89 (2H, b), 4.30–4.35 (1H, m), 4.70–4.78 (1H, m,
CH2CHCOOH), 5.97–6.01 (1H, m, H-11), 6.94 (1H, d, J = 8 Hz,
NHCOCH3), 8.55 (1H, d, J = 12 Hz, H-20), 9.83–9.88 (1H, m, C20NH).
To synthesize 3, Wm (17.1 mg, 0.04 mmol), N-acetyl-cysteine (13
mg, 0.08 mmol), and triethylamine (0.4 ml) were mixed in CH2Cl2 (1
ml). After 1.5 hr of stirring, the reaction mixture was concentrated un-
der reduced pressure. The residue was purified by HPLC (system 3),
and a yellow powderwas obtained after lyophilization. Subsequent pu-
rity analysis by HPLC (system 4) revealed the presence of a minor im-
purity, accounting for less than 20% of total. Yield: 19.4 mg, 81.8%.
MS: C28H33N2O11S, cal. 592.1852, found 592.1856 (M+H
+); 1H NMR,
(CDCl3): 0.82 (3H, s, 13-CH3), 1.52 (3H, s, 10-CH3), 1.70–2.01 (3H, b),
2.05 (3H, s, NHCOCH3), 2.09 (3H, s, CH3COO), 2.22–2.40 (3H, m),
2.54–2.64 (1H, m), 2.80–2.90 (1H, m), 2.94–3.00 (1H, m), 3.14–3.34
(2H, m, H-15), 3.26 (3H, s, CH3OCH2), 3.40–3.50 (2H, AB, J1 = 4 Hz,
J2 = 16 Hz, SCH2), 4.46 (1H, d, J = 4 Hz, H-1), 4.98–5.00 (1H, m,
CHCOOH), 5.98–6.01 (1H, m, H-11), 6.59 (1H, d, J = 8 Hz, NHCOCH3),
8.78 (1H, s, H-20).
To synthesize 4, WmC20-NMeHA was synthesized as described
[16].
Reaction of Wm with Amino Acid Side Chains or Proline
A total of 10 ml Wm (0.058 mM in DMSO) was diluted in 400 ml PBS
buffer (pH 6.8). To this solution, 1000 equivalents of the appropriate
N-protected amino acid in DMSO or PBS buffer were added. If neces-
sary, 10–30 ml acetonitrile was added to completely solubilize the reac-
tion mixture. Solutions were incubated at 37C for the indicated time
and were analyzed by applying 10 ml plus 1 ml internal standard (1 mg
methyl-4-hyrdroxybenzoate [MHB]) to the HPLC column. System 4
and system 5 were used for HPLC.
Exchange Reactions
WmC20 derivatives 1, 2, or 3 at 0.3mM in PBS (pH 6.8) were incubated
with 3 mM N-acetyl-lysine, proline, or N-acetyl-cysteine at 37C for 24
hr. The reactionwasmonitored byHPLCwith system 4, by injecting the
reaction mixture (10 ml) with the MHB internal standard (1 ml, 1 mg/ml).
Antiproliferative and PI3 Kinase Assays
A549 cells were grown in RPMI-1640 supplemented with 10% FBS,
100 U/ml penicillin, 100 mg/ml streptomycin, and 2 mM L-glutamine.
All cells were grown in a humidified atmosphere at 37C and 5%
CO2. Growth inhibition was evaluated by the SRB assay [28]. Cells
were seeded in 96-well plates at 5000 cells per well in 100 ml media
and were incubated at 37C for 24 hr. Cells were then treated with
0–100 mM compounds 1–3 at 37C for 48 r. Cells were fixed with 50
ml cold 50% TCA, incubated at 4C for 1 hr, and washed five times
with tap water. The 96-well plates were allowed to air dry, and 100 ml
0.4% sulforhodamine B (SRB) in 1% acetic acid was added to each
well. After 10 min, the unbound SRB was washed away with 1% acetic
acid, and the plates were dried. Protein-bound dye was solubilized byChemistry & Biology 14, 32the addition of 200 ml 10 mM Tris buffer and subsequent shaking at
room temperature for 10 min. Absorbance was measured at 490 nm,
by a microtiter plate reader. Percent cell survival was calculated for
each concentration by the ratio of the measured absorbance to the ab-
sorbance of the untreated cells. The PI3 kinase enzyme assay was the
fluorescent energy transfer method [29]. The assay has higher IC50s for
Wm (12 nM) than radioactive lipid phosphorylation assays (1–4 nM)
because it uses a higher ATP concentration (100 mM). IC50s for both
assays were determined by curve fitting performed by using Prism
4.0a software.
Antiproliferative Activity of Wm Aged in Culture Media
Wmwas incubated in RPMI 1640 media at 37C for up to 240 min and
then added to A549 cells. Cell survival was determined after 48 hr as
described above.
Generation of Wm from WmC20 Derivatives
Solutions of 1, 2, 3, and 4 (1.88 mM) were made by reconstituting pow-
dered WmC20 derivatives with PBS (pH 7.0) and were incubated at
25C for 30min. They were analyzed by applying 10 ml plus 1 ml internal
standard (1 mg MHB) to the HPLC. System 4 was used for compounds
1–3, and system 5 was used for compound 4.
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